

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6072709

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED	04/21/2020
OCERA THERAPEUTICS, INC.	04/21/2020
ST SHARED SERVICES LLC	04/21/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
<b>Street Address:</b>	500 DELAWARE AVENUE
<b>City:</b>	WILMINGTON
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	19801
<b>PROPERTY NUMBERS Total: 13</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16724786
Application Number:	16704530
Application Number:	16748319
Application Number:	16677435
Application Number:	16696142
Application Number:	16779912
Application Number:	16785983
Application Number:	16785978
Application Number:	62948513
Application Number:	16778696
Application Number:	16732861
Application Number:	62965330
Application Number:	16779796
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	

**Phone:** 800-494-5225  
**Email:** ipteam@cogencyglobal.com  
**Correspondent Name:** STEWART WALSH  
**Address Line 1:** 1025 VERMONT AVE NW, SUITE 1130  
**Address Line 2:** COGENCY GLOBAL INC.  
**Address Line 4:** WASHINGTON, D.C. 20005

<b>ATTORNEY DOCKET NUMBER:</b>	1212548 PAT
<b>NAME OF SUBMITTER:</b>	JORDANA DREYFUSS
<b>SIGNATURE:</b>	/Jordana Dreyfuss/
<b>DATE SIGNED:</b>	04/22/2020

**Total Attachments: 6**

source=MNK - April 2020 IP Supplement - 2L Notes - Notice of Grant of Security Interest in Patents [For Filing]#page2.tif  
source=MNK - April 2020 IP Supplement - 2L Notes - Notice of Grant of Security Interest in Patents [For Filing]#page3.tif  
source=MNK - April 2020 IP Supplement - 2L Notes - Notice of Grant of Security Interest in Patents [For Filing]#page4.tif  
source=MNK - April 2020 IP Supplement - 2L Notes - Notice of Grant of Security Interest in Patents [For Filing]#page5.tif  
source=MNK - April 2020 IP Supplement - 2L Notes - Notice of Grant of Security Interest in Patents [For Filing]#page6.tif  
source=MNK - April 2020 IP Supplement - 2L Notes - Notice of Grant of Security Interest in Patents [For Filing]#page7.tif

**Notice of Grant of Security Interest in Intellectual Property**

NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS, dated as of April 21, 2020 (this “**Agreement**”), made by Mallinckrodt Hospital Products IP Limited, a private limited company incorporated in Ireland with registered number 568351, Ocera Therapeutics, Inc., a Delaware corporation, and ST Shared Services LLC, a Delaware limited liability company (each a “**Pledgor**”), in favor of Wilmington Savings Fund Society, FSB, as Second Lien Collateral Agent (as defined below).

Reference is made to the Second Lien U.S. Collateral Agreement dated as of December 6, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the “**Second Lien U.S. Collateral Agreement**”), among Mallinckrodt International Finance S.A., a public limited liability company (*société anonyme*) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 124 boulevard de la Pétrusse, L-2330 Luxembourg, and registered with the Luxembourg Trade and Companies Register (*R.C.S Luxembourg*) under number B 172.865 (the “**Issuer**”), Mallinckrodt CB LLC, a Delaware limited liability company (the “**US Co-Issuer**”, and together with the Issuer, the “**Issuers**”), each Guarantor listed on the signature pages thereof and each other Guarantor that becomes a party thereto after the Issue Date (together with the Issuer and the US Co-Issuer, collectively, the “**Pledgors**”) and Wilmington Savings Fund Society, FSB, as Second Lien Collateral Agent (together with its successors and assigns in such capacity, the “**Second Lien Collateral Agent**”) for the Secured Parties (as defined therein). The parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Second Lien U.S. Collateral Agreement. The rules of construction specified in Section 1.01(b) of the Second Lien U.S. Collateral Agreement also apply to this Agreement.

SECTION 2. **Grant of Security Interest.** As security for the payment and performance, as applicable, in full of its Secured Obligations, each Pledgor pursuant to the Second Lien U.S. Collateral Agreement did, and hereby does, assign and pledge to the Second Lien Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in all of such Pledgor’s right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by such Pledgor or in which such Pledgor now has or at any time in the future may acquire any right, title or interest (collectively, but excluding any Excluded Property, the “**IP Collateral**”):

all Patents of the United States of America, including those listed on Schedule I;

SECTION 3. **Second Lien U.S. Collateral Agreement.** The security interests granted to the Second Lien Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Second Lien Collateral Agent pursuant to the Second Lien U.S. Collateral Agreement. Each Pledgor hereby acknowledges and affirms that the rights and remedies of the Second Lien Collateral Agent with respect to the IP Collateral are more fully set forth in the Second Lien U.S. Collateral Agreement, the terms and provisions of which are hereby incorporated herein

by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Second Lien U.S. Collateral Agreement, the terms of the Second Lien U.S. Collateral Agreement shall govern.

SECTION 4. *Counterparts*. This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart to this Agreement by facsimile or other electronic transmission shall be as effective as delivery of a manually signed original.

SECTION 5. *Governing Law*. **THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.**

SECTION 6 Notwithstanding anything herein to the contrary, the lien and security interest granted to the Second Lien Collateral Agent pursuant to this Agreement and the exercise of any right or remedy by the Second Lien Collateral Agent hereunder are subject to the provisions of the First Priority/Second Priority Intercreditor Agreement. In the event of any conflict between the terms of the First Priority/Second Priority Intercreditor Agreement and this Agreement, the terms of the First Priority/Second Priority Intercreditor Agreement shall govern and control

[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

MALLINCKRODT HOSPITAL PRODUCTS IP  
LIMITED

By: \_\_\_\_\_  
Name: Alasdair Fenlon  
Title: Director

OCERA THERAPEUTICS, INC.

By: \_\_\_\_\_  
Name: John Einwalter  
Title: Vice President & Treasurer

ST SHARED SERVICES LLC

By: \_\_\_\_\_  
Name: John Einwalter  
Title: Vice President & Treasurer


[Notice of Grant of Security Interest in Patents (2L Notes)]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

MALLINCKRODT HOSPITAL PRODUCTS IP  
LIMITED

By: \_\_\_\_\_  
Name: Alasdair Fenlon  
Title: Director


OCERA THERAPEUTICS, INC.

By:  \_\_\_\_\_  
Name: John Einwalter  
Title: Vice President & Treasurer

ST SHARED SERVICES LLC

By:  \_\_\_\_\_  
Name: John Einwalter  
Title: Vice President & Treasurer

WILMINGTON SAVINGS FUND SOCIETY, FSB,  
as Second Lien Collateral Agent

By:   
Name: Raye Goldsborough  
Title: Assistant Vice President

By: \_\_\_\_\_  
Name:  
Title:

Schedule I  
to Notice of Grant of Security Interest in Patents

**U.S. Federally Issued or Applied for Patents.**

<b>Patent</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Owner</b>
APPARATUS AND METHOD FOR DETECTING LIQUID LEVEL IN A CLEAR OR PARTIALLY CLEAR CONTAINER	16/724786	12/23/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
ENHANCED PERFORMANCE VERIFICATION PORT FOR THERAPEUTIC GAS DELIVERY	16/704530	12/5/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
SYSTEMS AND METHODS FOR DELIVERY OF THERAPEUTIC GAS	16/748319	1/21/2020	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
CLINICAL DECISION SUPPORT SYSTEM AND METHODS	16/677435	11/7/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
SYSTEMS AND METHODS FOR INDICATING LIFETIME OF AN NO <sub>2</sub> -TO-NO REACTOR CARTRIDGE USED TO DELIVER NO FOR INHALATION THERAPY TO A PATIENT	16/696142	11/26/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
SYSTEM AND METHOD OF ADMINISTERING A PHARMACEUTICAL GAS TO A PATIENT	16/779912	2/3/2020	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
METHODS OF ADMINISTERING HIGH CONCENTRATIONS OF NITRIC OXIDE	16/785983	2/10/2020	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
CANNULA FOR MINIMIZING DILUTION OF DOSING DURING NITRIC OXIDE DELIVERY	16/785978	2/10/2020	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
METHODS FOR TREATING PROGRESSIVE HYPERBILIRUBINEMIA	62/948513	12/16/2019	MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF	16/778696	1/31/2020	OCERA THERAPEUTICS, INC.
TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STELLATE CELL ACTIVATION USING AMMONIA-LOWERING THERAPIES	16/732861	1/2/2020	OCERA THERAPEUTICS, INC.
DOSAGES AND USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA	62/965330	1/24/2020	OCERA THERAPEUTICS, INC.
(+)-MORPHINAN COMPOUNDS AS SMALL MOLECULE ANTAGONISTS OF TOLL-LIKE RECEPTOR 9	16/779796	2/3/2020	ST SHARED SERVICES LLC